Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01827930 | Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response(MIM) | terminated | Phase 3 | 68 | Institut BergoniéOTHER | 1 | Dec 31, 2020 | clinicaltrials |
| NCT00452439 | A Study of Actonel for the Prevention of Bone Loss | completed | Phase 3 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 28, 2020 | clinicaltrials |
| NCT03530085 | Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT | unknown | Phase 2 / Phase 3 | 60 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Dec 22, 2020 | clinicaltrials |
| NCT02951156 | Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)(Javelin DLBCL) | terminated | Phase 3 | 29 | PfizerINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
| NCT01371656 | Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation | completed | Phase 3 | 624 | Children's Oncology GroupNETWORK | 2 | Dec 7, 2020 | clinicaltrials |
| NCT04000698 | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias | unknown | Phase 3 | 25 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 | Nov 18, 2020 | clinicaltrials |
| NCT00577993 | Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients | completed | Phase 3 | 210 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 16, 2020 | clinicaltrials |
| NCT00515554 | HD18 for Advanced Stages in Hodgkins Lymphoma | completed | Phase 3 | 1,500 | University of CologneOTHER | 1 | Nov 13, 2020 | clinicaltrials |
| NCT01102426 | Aplidin - Dexamethasone in Relapsed/Refractory Myeloma(ADMYRE) | completed | Phase 3 | 255 | PharmaMarINDUSTRY | 19 | Nov 10, 2020 | clinicaltrials |
| NCT00736320 | HD16 for Early Stage Hodgkin Lymphoma(HD16) | unknown | Phase 3 | 1,150 | University of CologneOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00551239 | Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02809053 | A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma(RAMO-2) | completed | Phase 3 | 315 | Archigen Biotech LimitedINDUSTRY | 14 | Oct 8, 2020 | clinicaltrials |
| NCT02944045 | Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients(PIC) | unknown | Phase 3 | 222 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00577161 | Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL | withdrawn | Phase 3 | 0 | CTI BioPharmaINDUSTRY | 1 | Oct 5, 2020 | clinicaltrials |
| NCT01773187 | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis | terminated | Phase 3 | 327 | CTI BioPharmaINDUSTRY | 12 | Sep 29, 2020 | clinicaltrials |
| NCT02381379 | Malaysia Stop Tyrosine Kinase Inhibitor Trial(MSIT) | unknown | Phase 3 | 118 | Ministry of Health, MalaysiaOTHER_GOV | 1 | Sep 14, 2020 | clinicaltrials |
| NCT00137111 | Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia | completed | Phase 3 | 501 | St. Jude Children's Research HospitalOTHER | 1 | Sep 11, 2020 | clinicaltrials |
| NCT02657785 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02836158 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | recruiting | Phase 2 / Phase 3 | 100 | Navy General Hospital, BeijingOTHER | 1 | Sep 9, 2020 | clinicaltrials |
| NCT04539119 | Entecavir and Tenofovir Versus Entecavir in Lymphoma Patients With Positive HBV DNA | unknown | Phase 3 | 120 | Ruijin HospitalOTHER | 1 | Sep 4, 2020 | clinicaltrials |
| NCT03242902 | To Decrease Fatigue With Light Therapy(SPARKLE) | completed | Phase 3 | 166 | The Netherlands Cancer InstituteOTHER | 1 | Sep 1, 2020 | clinicaltrials |
| NCT00491491 | Zevalin-beam for Aggressive Lymphoma | completed | Phase 3 | 60 | Sheba Medical CenterOTHER_GOV | 4 | Aug 31, 2020 | clinicaltrials |
| NCT01889069 | A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Rituximab (MabThera/Rituxan) in Participants With Diffuse Large B Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) | completed | Phase 3 | 159 | Hoffmann-La RocheINDUSTRY | 1 | Aug 13, 2020 | clinicaltrials |
| NCT02867566 | A Study Comparing the Efficacy and Safety Between I-CHOP and R-CHOP in Untreated CD20-Positive Diffuse Large B-cell Lymphoma Patients | completed | Phase 3 | 420 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Aug 12, 2020 | clinicaltrials |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | unknown | Phase 2 / Phase 3 | 100 | Chinese PLA General HospitalOTHER | 1 | Aug 12, 2020 | clinicaltrials |
| NCT00006083 | Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter | completed | Phase 3 | — | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00070382 | Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer | completed | Phase 3 | 14 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT01602211 | INSPIRE: Internet and Social-media Program With Information and Resources for Long-Term Cancer Survivors Who Underwent Stem Cell Transplant(INSPIRE) | completed | Phase 3 | 1,600 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 31, 2020 | clinicaltrials |
| NCT00822393 | Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC) | completed | Phase 3 | 570 | medac GmbHINDUSTRY | 6 | Jul 30, 2020 | clinicaltrials |
| NCT00750009 | Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial | completed | Phase 3 | 583 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 27, 2020 | clinicaltrials |
| NCT01285765 | Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients | completed | Phase 3 | 650 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 14, 2020 | clinicaltrials |
| NCT03628053 | Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia(OBERON) | withdrawn | Phase 3 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Jul 9, 2020 | clinicaltrials |
| NCT03593304 | Evaluate the Neuroprotective Effect of Vitamin B6 and Vitamin B12 Against Vincristine Induced Neurotoxicity in Acute Lymphoblastic Leukaemia Patients | completed | Phase 2 / Phase 3 | 40 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT01241500 | Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts(ONTIME) | completed | Phase 3 | 299 | Traws Pharma, Inc.INDUSTRY | 6 | Jun 30, 2020 | clinicaltrials |
| NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine | completed | Phase 3 | 67 | Traws Pharma, Inc.INDUSTRY | 8 | Jun 30, 2020 | clinicaltrials |
| NCT01854567 | P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies | completed | Phase 3 | 49 | Mesoblast, Ltd.INDUSTRY | 1 | Jun 26, 2020 | clinicaltrials |
| NCT04446130 | Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients | unknown | Phase 3 | 100 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 24, 2020 | clinicaltrials |
| NCT03483194 | Therapeutic Virtual Reality : Impact on the Management of Pain and Anxiety Related to Hematology Care (REVEH)(REVEH) | completed | Phase 2 / Phase 3 | 126 | WepromOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT00824265 | Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia | completed | Phase 3 | 365 | Novartis PharmaceuticalsINDUSTRY | 18 | Jun 18, 2020 | clinicaltrials |
| NCT02650791 | Platelet Transfusion Requirements in Hematopoietic Transplantation Pilot Study(PATH) | completed | Phase 3 | 100 | Ottawa Hospital Research InstituteOTHER | 1 | May 18, 2020 | clinicaltrials |
| NCT02322320 | Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT) | completed | Phase 3 | 273 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | May 11, 2020 | clinicaltrials |
| NCT00513747 | Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | terminated | Phase 3 | 84 | Alliance for Clinical Trials in OncologyOTHER | 2 | Apr 22, 2020 | clinicaltrials |
| NCT01413178 | A Randomized Trial to Compare Busulfan + Melphalan 140 mg/m2 With Melphalan 200 mg/m2 as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma | completed | Phase 3 | 205 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 21, 2020 | clinicaltrials |
| NCT00002561 | Radiation Therapy and Chemotherapy in Treating Patients With Hodgkin's Disease | completed | Phase 3 | 405 | NCIC Clinical Trials GroupNETWORK | 3 | Apr 14, 2020 | clinicaltrials |
| NCT00219739 | STI571 ProspectIve RandomIzed Trial: SPIRIT(SPIRIT) | completed | Phase 3 | 789 | Poitiers University HospitalOTHER | 1 | Apr 13, 2020 | clinicaltrials |
| NCT00720109 | Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 / Phase 3 | 63 | National Cancer Institute (NCI)NIH | 5 | Apr 13, 2020 | clinicaltrials |
| NCT01829711 | Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia | completed | Phase 3 | 80 | MedImmune LLCINDUSTRY | 14 | Apr 8, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Dec 31, 2020source: clinicaltrials